VRPX vs. EYEN, PLRZ, ADXS, PTEIQ, ASLN, CWBR, SLRX, BPTSY, PCSA, and BPTH
Should you be buying Virpax Pharmaceuticals stock or one of its competitors? The main competitors of Virpax Pharmaceuticals include Eyenovia (EYEN), Polyrizon (PLRZ), Ayala Pharmaceuticals (ADXS), PolarityTE (PTEIQ), ASLAN Pharmaceuticals (ASLN), CohBar (CWBR), Salarius Pharmaceuticals (SLRX), Biophytis (BPTSY), Processa Pharmaceuticals (PCSA), and Bio-Path (BPTH). These companies are all part of the "pharmaceutical products" industry.
Virpax Pharmaceuticals vs.
Eyenovia (NASDAQ:EYEN) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.
Eyenovia has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, Virpax Pharmaceuticals has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500.
Eyenovia received 171 more outperform votes than Virpax Pharmaceuticals when rated by MarketBeat users. Likewise, 64.21% of users gave Eyenovia an outperform vote while only 60.00% of users gave Virpax Pharmaceuticals an outperform vote.
Virpax Pharmaceuticals has a net margin of 0.00% compared to Eyenovia's net margin of -114,639.41%. Eyenovia's return on equity of -1,108.24% beat Virpax Pharmaceuticals' return on equity.
In the previous week, Eyenovia had 2 more articles in the media than Virpax Pharmaceuticals. MarketBeat recorded 2 mentions for Eyenovia and 0 mentions for Virpax Pharmaceuticals. Eyenovia's average media sentiment score of 1.43 beat Virpax Pharmaceuticals' score of 0.00 indicating that Eyenovia is being referred to more favorably in the media.
Eyenovia currently has a consensus price target of $2.00, suggesting a potential upside of 73.91%. Virpax Pharmaceuticals has a consensus price target of $75.00, suggesting a potential upside of 28,746.15%. Given Virpax Pharmaceuticals' higher possible upside, analysts clearly believe Virpax Pharmaceuticals is more favorable than Eyenovia.
25.8% of Eyenovia shares are held by institutional investors. Comparatively, 32.2% of Virpax Pharmaceuticals shares are held by institutional investors. 7.1% of Eyenovia shares are held by company insiders. Comparatively, 3.7% of Virpax Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Virpax Pharmaceuticals has lower revenue, but higher earnings than Eyenovia.
Summary
Eyenovia beats Virpax Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
Get Virpax Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRPX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Virpax Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:VRPX) was last updated on 5/1/2025 by MarketBeat.com Staff
Buy VRPX Stock Free VRPX Stock Alerts